Sobre o projeto
Algae4IBD's mission is to develop commercial products for Inflammatory Bowel Disease (IBD) prevention and treatment using aquatic natural biological resources. Micro and macroalgae, found in marine and freshwater, have been identified as promising sources of bioactive compounds including small molecules and secondary metabolites with a wide range of bioactivities as an antioxidant, anti-inflammatory and cancer preventive.
ALGAE4IBD - From Nature to Bedside - Algae Based Bio Compound for Prevention and Treatment of Inflammation, Pain and IBD
Atividades
With the objective of creating an innovative ‘natural source to bedside pipeline’ in order to identify novel small molecules from micro- and macroalgae origin (according to the EU Green Deal approach) for the prevention and treatment of inflammation, pain and IBD, Algae4IBD project will establish unique and exclusive Algae4IBD algae strain bank that will include pre-indicated and understudied micro and macro-algae in order to provide excessive knowledge for their bio activities. Thus, to develop and products prototype for inflammation pain and IBD using both preventive
approach (e.g. functional food, food supplements) and as algae-based treatment approach (pharma use).
CCMAR is involved in
- WP1 - Screening of algae, with the selection of algae based on their anti-inflammatory activities and the extraction of target compounds from the provided biomass of 150 different algae strains;
- WP2 - Bioactivity screening, with the employment of HPLC-based bioactivity guided fractionation for chemical characterization of a wide variety of known bioactive compounds;
- WP5 - Bioactive compounds synthesis and algae improvement, where bioactive compound purification will be employed with NMR analysis. This will enable the synthesis of the compound moiety responsible for the biological activity, which may have a simpler structure that is easier to synthesize.
Coordenação do CCMAR
Project partners
